Condition (MeSH)
Stuttering
ClinicalTrials.gov lists 70 trials for Stuttering or a narrower condition beneath it. National Institute on Deafness and Other Communication Disorders (NIDCD) has the most among industry and government lead sponsors, with 4.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
70 of the 70 trials are tagged with Stuttering itself; the rest are tagged with a narrower condition beneath it.
When did Stuttering trials start? (24)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 9
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 12 |
| 2025 | 5 |
| 2024 | 2 |
| 2023 | 6 |
| 2022 | 9 |
| 2021 | 5 |
| 2020 | 5 |
| 2019 | 1 |
| 2018 | 3 |
| 2017 | 3 |
Showing 10 of 24 earlier years.
Forecast of the full-year count, planned starts included, not rows of this table: about 13 trials starting in 2026 and about 8 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.
Prediction, not a registry value: median of 31 months from start to primary completion across 16 trials still running at the 2026-10-09 snapshot; registered median of 16 months across 28 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Stuttering trials in? (7)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 5 |
| Phase 2/3 | 2 |
| Phase 3 | 1 |
| Phase 4 | 1 |
| Not applicable | 45 |
| Observational | 14 |
How many Stuttering trials are recruiting? (9)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 3 |
| Recruiting | 16 |
| Enrolling by invitation | 1 |
| Active, not recruiting | 1 |
| Completed | 27 |
Showing 5 of 9 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Stuttering trials? (3)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Institute on Deafness and Other Communication Disorders (NIDCD) | 4 |
| National Institute of Neurological Disorders and Stroke (NINDS) | 2 |
| CSTrials Inc. | 1 |
Which drugs are being tested for Stuttering? (4)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Ecopipam | 2 |
| Pagoclone | 1 |
| Lumateperone | 1 |
| Aripiprazole | 1 |
Interventions as named in the registry (6)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Combination Group | 1 |
| Hyperbaric Oxygen | 1 |
| Transcranial Magnetic Stimulation | 1 |
| IV Psilocybin | 1 |
| Adjunctive asenapine | 1 |
Showing 5 of 6 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which publications cover Stuttering? (75)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| The application of neuronavigated rTMS of the supplementary motor area and rhythmic speech training for stuttering intervention. | International journal of language & communication disorders | 2024 | Yes |
| Altered engagement of the speech motor network is associated with reduced phonological working memory in autism. | NeuroImage. Clinical | 2023 | Yes |
| The effect of tele-speech therapy on treatment of stuttering. | Disability and rehabilitation. Assistive technology | 2022 | Yes |
| Developmental stuttering and the role of the supplementary motor cortex. | Journal of fluency disorders | 2020 | Yes |
| Neuronavigated rTMS inhibition of right pars triangularis anterior in stuttering: Differential effects on reading and speaking. | Brain and language | 2020 | Yes |
Showing 5 of 75 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: serious adverse events in this condition's trials, prevalence, rare-disease identity, and sub-conditions in mesh.